Prostaglandins and fatty acids regulate transcriptional signaling via the peroxisome proliferator activated receptor nuclear receptors

Prostaglandins and Other Lipid Mediators

Volumn 62, Issue 1, 2000, Pages 1-13

  Dussault, Isabelle ^a   Forman, Barry M ^a  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; 4 [4 [3 (4 ACETYL 3 HYDROXY 2 PROPYLPHENOXY)PROPOXY]PHENOXY]ACETIC ACID; ANTIDIABETIC AGENT; CARBACYCLIN; CELL NUCLEUS RECEPTOR; INDOMETACIN; L 796449; N (2 BENZOYLPHENYL) O [2 (METHYL 2 PYRIDINYLAMINO)ETHYL]TYROSINE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PIOGLITAZONE; POLYUNSATURATED FATTY ACID; PROSTACYCLIN DERIVATIVE; PROSTAGLANDIN DERIVATIVE; RECEPTOR SUBTYPE; ROSIGLITAZONE; TROGLITAZONE; UNCLASSIFIED DRUG;

CANCER INHIBITION; CELL SPECIFICITY; HOMEOSTASIS; HUMAN; INSULIN SENSITIVITY; LIGAND BINDING; NONHUMAN; REVIEW; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION;

ANIMALS; FATTY ACIDS; HUMANS; PROSTAGLANDINS; RECEPTORS, CYTOPLASMIC AND NUCLEAR; SIGNAL TRANSDUCTION; TRANSCRIPTION FACTORS; TRANSCRIPTION, GENETIC;

EID: 0033885498     PISSN: 00906980     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-6980(00)00071-X     Document Type: Review

References (85)

1. Smith W.L. The eicosanoids and their biochemical mechanisms of action. Biochem J. 259:1989;315-324.
2. Smith W.L. Prostanoid biosynthesis and mechanisms of action. Am J Physiol. 263:1992;F181-F191.
3. Hirata Y., Hayashi H., Ito S., et al. Occurrence of 9-deoxy-δ 9, delta 12-13,14-dihydroprostaglandin D2 in human urine. J Biol Chem. 263:1988;16619-16625.
4. Narumiya S., Ohno K., Fujiwara M., Fukushima M. Site and mechanism of growth inhibition by prostaglandins. II. Temperature-dependent transfer of a cyclopentenone prostaglandin to nuclei. J Pharmacol Exp Ther. 239:1986;506-511.
5. Narumiya S., Ohno K., Fukushima M., Fujiwara M. Site and mechanism of growth inhibition by prostaglandins. III. Distribution and binding of prostaglandin A2 and delta 12-prostaglandin J2 in nuclei. J Pharmacol Exp Ther. 242:1987;306-311.
6. Forman B.M., Tontonoz P., Chen J., Brun R.P., Spiegelman B.M., Evans R.M. 15-Deoxy-δ 12, 14-prostaglandin J2 is a ligand for the adipocyte determination factor PPAR gamma. Cell. 83:1995;803-812.
7. Kliewer S.A., Lenhard J.M., Willson T.M., Patel I., Morris D.C., Lehmann J.M. A prostaglandin J2 metabolite binds peroxisome proliferator-activated receptor gamma and promotes adipocyte differentiation. Cell. 83:1995;813-819.
8. Fukushima M. Biological activities and mechanisms of action of PGJ2 and related compounds an update . Prostaglandins Leukotrienes Essent Fatty Acids. 47:1992;1-12.
9. Ohno K., Fukushima M., Fujiwara M., Narumiya S. Induction of 68,000-dalton heat shock proteins by cyclopentenone prostaglandins. Its association with prostaglandin-induced G1 block in cell cycle progression. J Biol Chem. 263:1988;19764-19770.
10. Shimizu Y., Todo S., Imashuku S. Selective synthesis and retention of 66k protein in a human neuroblastoma cell line (NCG) treated with a cytotoxic dosage of delta 12-prostaglandin J2. Prostaglandins. 34:1987;769-781.
11. Santoro M.G., Garaci E., Amici C. Prostaglandins with antiproliferative activity induce the synthesis of a heat shock protein in human cells. Proc Natl Acad Sci USA. 86:1989;8407-8411.
12. Mangelsdorf D.J., Thummel C., Beato M., et al. The nuclear receptor superfamily the second decade . Cell. 83:1995;835-839.
13. Mangelsdorf D.J., Evans R.M. The RXR heterodimers and orphan receptors. Cell. 83:1995;841-850.
14. Evans R.M. The steroid and thyroid hormone receptor superfamily. Science. 240:1988;889-895.
15. Green S., Chambon P. Nuclear receptors enhance our understanding of transcription regulation. Trends Genet. 4:1988;309-314.
16. Spencer T.E., Jenster G., Burcin M.M., et al. Steroid receptor coactivator-1 is a histone acetyltransferase. Nature (London). 389:1997;194-198.
17. Fondell J.D., Ge H., Roeder R.G. Ligand induction of a transcriptionally active thyroid hormone receptor coactivator complex. Proc Natl Acad Sci USA. 93:1996;8329-8333.
18. Rachez C., Suldan Z., Ward J., et al. A novel protein complex that interacts with the vitamin D3 receptor in a ligand-dependent manner and enhances VDR transactivation in a cell- free system. Genes Dev. 12:1998;1787-1800.
19. Yuan CX, Ito M, Fondell JD, Fu ZY, Roeder RG. The TRAP220 component of a thyroid hormone receptor- associated protein (TRAP) coactivator complex interacts directly with nuclear receptors in a ligand-dependent fashion [published erratum appears in Proc Natl Acad Sci USA 1998 Nov 24;95:14584]. Proc Natl Acad Sci USA 1998; 95:7939-44.
20. Yuan CX, Ito M, Fondell JD, Fu ZY, Roeder RG. The TRAP220 component of a thyroid hormone receptor- associated protein (TRAP) coactivator complex interacts directly with nuclear receptors in a ligand-dependent fashion [published erratum appears in Proc Natl Acad Sci USA 1998 Nov 24;95:14584]. Proc Natl Acad Sci USA 1998; 95:7939-44.
21. Giguere V., Yang N., Segui P., Evans R.M. Identification of a new class of steroid hormone receptors. Nature (London). 331:1988;91-94.
22. Webster N.J., Green S., Jin J.R., Chambon P. The hormone-binding domains of the estrogen and glucocorticoid receptors contain an inducible transcription activation function. Cell. 54:1988;199-207.
23. Samuels H.H., Stanley F., Casanova J. Depletion of L-3,5,3′-triiodothyronine and L-thyroxine in euthyroid calf serum for use in cell culture studies of the action of thyroid hormone. Endocrinology. 105:1979;80-85.
24. Stanley F., Tsai J.S., Samuels H.H. Stimulation of facilitated [3H]uridine transport by thyroid hormone in GH1 cells. Evidence for regulation by the thyroid hormone nuclear receptor. J Biol Chem. 261:1986;9400-9404.
25. Forman B.M., Chen J., Evans R.M. Hypolipidemic drugs, polyunsaturated fatty acids and eicosanoids are ligands for peroxisome proliferator-activated receptors α and δ Proc Natl Acad Sci USA. 94:1997;4312-4317.
26. Krey G., Braissant O., L'Horset F., et al. Fatty acids, eicosanoids, and hypolipidemic agents identified as ligands of peroxisome proliferator-activated receptors by coactivator-dependent receptor ligand assay. Mol Endocrinol. 11:1997;779-791.
27. Hess R., Staubli W., Riess W. Nature of the hepatomegalic effect produced by ethyl-chlorophenoxy-isobutyrate in the rat. Nature (London). 208:1965;856-858.
28. de la Iglesia F., McGuire E.J., Haskins J.R., Lalwani N.D. Structural diversity of peroxisome proliferators and their effects on mammalian liver cells in vivo. Ann N Y Acad Sci. 804:1996;310-327.
29. Issemann I., Green S. Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators. Nature (London). 347:1990;645-650.
30. Dreyer C., Krey G., Keller H., Givel F., Helftenbein G., Wahli W. Control of the peroxisomal β-oxidation pathway by a novel family of nuclear hormone receptors. Cell. 68:1992;879-887.
31. Kliewer S.A., Forman B.M., Blumberg B., et al. Differential expression and activation of a family of murine peroxisome proliferator-activated receptors. Proc Natl Acad Sci USA. 91:1994;7355-7359.
32. Zhu Y., Alvares K., Huang Q., Rao M.S., Reddy J.K. Cloning of a new member of the peroxisome proliferator-activated receptor gene family from mouse liver. J Biol Chem. 268:1993;26817-26820.
33. Chen F., Law S.W., O'Malley B.W. Identification of two mPPAR related receptors and evidence for the existence of five subfamily members. Biochem Biophys Res Commun. 196:1993;671-677.
34. Tontonoz P., Hu E., Spiegelman B.M. Stimulation of adipogenesis in fibroblasts by PPAR gamma 2, a lipid-activated transcription factor. Cell. 79:1994;1147-1156.
35. Schmidt A., Endo N., Rutledge S.J., Vogel R., Shinar D., Rodan G.A. Identification of a new member of the steroid hormone receptor superfamily that is activated by a peroxisome proliferator and fatty acids. Mol Endocrinol. 6:1992;1634-1641.
36. Kliewer S.A., Umesono K., Noonan D.J., Heyman R.A., Evans R.M. Convergence of 9-cis retinoic acid and peroxisome proliferator signalling pathways through heterodimer formation of their receptors. Nature (London). 358:1992;771-774.
37. Palmer C.N.A., Hsu M.H., Griffin K.J., Johnson E.F. Novel sequence determinants in peroxisome proliferator signaling. J Biol Chem. 270:1995;16114-16121.
38. Greene M.E., Blumberg B., McBride O.W., et al. Isolation of the human peroxisome proliferator activated receptor gamma cDNA expression in hematopoietic cells and chromosomal mapping . Gene Expr. 4:1995;281-299.
39. Tontonoz P., Hu E., Graves R.A., Budavari A.I., Spiegelman B.M. mPPAR gamma 2 tissue-specific regulator of an adipocyte enhancer. Genes Dev. 8:1994;1224-1234.
40. Tontonoz P., Nagy L., Alvarez J.G., Thomazy V.A., Evans R.M. PPARgamma promotes monocyte/macrophage differentiation and uptake of oxidized LDL. Cell. 93:1998;241-252.
41. Mansen A., Guardiola-Diaz H., Rafter J., Branting C., Gustafsson J.A. Expression of the peroxisome proliferator-activated receptor (PPAR) in the mouse colonic mucosa. Biochem Biophys Res Commun. 222:1996;844-851.
42. Auboeuf D., Rieusset J., Fajas L., et al. Tissue distribution and quantification of the expression of mRNAs of peroxisome proliferator-activated receptors and liver X receptor-α in humans no alteration in adipose tissue of obese and NIDDM patients . Diabetes. 46:1997;1319-1327.
43. Issemann I., Prince R.A., Tugwood J.D., Green S. The peroxisome proliferator-activated receptor:retinoid X receptor heterodimer is activated by fatty acids and fibrate hypolipidaemic drugs. J Mol Endocrinol. 11:1993;37-47.
44. Kliewer S.A., Sundseth S.S., Jones S.A., et al. Fatty acids and eicosanoids regulate gene expression through direct interactions with perxisome proliferator-activated receptors α and γ Proc Natl Acad Sci USA. 94:1997;4318-4323.
45. Yu K., Bayona W., Kallen C.B., et al. Differential activation of peroxisome proliferator-activated receptors by eicosanoids. J Biol Chem. 270:1995;23975-23983.
46. Furstenberger G., Hagedorn H., Jacobi T., et al. Characterization of an 8-lipoxygenase activity induced by the phorbol ester tumor promoter 12-O-tetradecanoylphorbol-13-acetate in mouse skin in vivo. J Biol Chem. 266:1991;15738-15745.
47. Hughes M.A., Brash A.R. Investigation of the mechanism of biosynthesis of 8-hydroxyeicosatetraenoic acid in mouse skin. Biochim Biophys Acta. 1081:1991;347-354.
48. Jisaka M., Kim R.B., Boeglin W.E., Nanney L.B., Brash A.R. Molecular cloning and functional expression of a phorbol ester-inducible 8S-lipoxygenase from mouse skin. J Biol Chem. 272:1997;24410-24416.
49. Moya-Camarena S.Y., Vanden Heuvel J.P., Blanchard S.G., Leesnitzer L.A., Belury M.A. Conjugated linoleic acid is a potent naturally occurring ligand and activator of PPARalpha. J Lipid Res. 40:1999;1426-1433.
50. Murakami K., Tobe K., Ide T., et al. A novel insulin sensitizer acts as a coligand for peroxisome proliferator-activated receptor-alpha (PPAR-alpha) and PPAR-gamma effect of PPAR-alpha activation on abnormal lipid metabolism in liver of Zucker fatty rats . Diabetes. 47:1998;1841-1847.
51. Murakami K., Ide T., Suzuki M., Mochizuki T., Kadowaki T. Evidence for direct binding of fatty acids and eicosanoids to human peroxisome proliferators-activated receptor alpha. Biochem Biophys Res Commun. 260:1999;609-613.
52. Lee S.S.T., Pineau T., Drago J., et al. Targeted disruption of the alpha Isoform of the peroxisome proliferator-activated receptor gene in mice results in abolishment of the pleiotropic effects of peroxisome proliferators. Mol Cell Biol. 15:1995;3012-3022.
53. Tontonoz P., Hu E., Devine J., Beale E.G., Spiegelman B.M. PPAR gamma 2 regulates adipose expression of the phosphoenolpyruvate carboxykinase gene. Mol Cell Biol. 15:1995;351-357.
54. Chinery R., Coffey R.J., Graves-Deal R., et al. Prostaglandin J2 and 15-deoxy-δ12,14-prostaglandin J2 induce proliferation of cyclooxygenase-depleted colorectal cancer cells. Cancer Res. 59:1999;2739-2746.
55. Ujihara M., Urade Y., Eguchi N., Hayashi H., Ikai K., Hayaishi O. Prostaglandin D2 formation and characterization of its synthetases in various tissues of adult rats. Arch Biochem Biophys. 260:1988;521-531.
56. Suzuki H., Kurihara Y., Takeya M., et al. A role for macrophage scavenger receptors in atherosclerosis and susceptibility to infection. Nature (London). 386:1997;292-296.
57. Matsumoto A., Naito M., Itakura H., et al. Human macrophage scavenger receptors primary structure, expression, and localization in atherosclerotic lesions . Proc Natl Acad Sci USA. 87:1990;9133-9137.
58. Yamada Y., Doi T., Hamakubo T., Kodama T. Scavenger receptor family proteins roles for atherosclerosis, host defence and disorders of the central nervous system . Cell Mol Life Sci. 54:1998;628-640.
59. Han J., Hajjar D.P., Febbraio M., Nicholson A.C. Native and modified low density lipoproteins increase the functional expression of the macrophage class B scavenger receptor, CD36. J Biol Chem. 272:1997;21654-21659.
60. Nagy L., Tontonoz P., Alvarez J.G., Chen H., Evans R.M. Oxidized LDL regulates macrophage gene expression through ligand activation of PPARgamma. Cell. 93:1998;229-240.
61. Huang J.T., Welch J.S., Ricote M., et al. IL-4-dependent production of PPAR-γ ligands in macrophages by 12/15-lipoxygenase. Nature (London). 400:1999;378-382.
62. Ricote M., Li A.C., Willson T.M., Kelly C.J., Glass C.K. The peroxisome proliferator-activated receptor-γ is a negative regulator of macrophage activation. Nature (London). 391:1998;79-82.
63. Jiang C., Ting A.T., Seed B. PPAR-γ agonists inhibit production of monocyte inflammatory cytokines. Nature (London). 391:1998;82-86.
64. Elstner E., Muller C., Koshizuka K., et al. Ligands for peroxisome proliferator-activated receptor gamma and retinoic acid receptor inhibit growth and induce apoptosis of human breast cancer cells in vitro and in BNX mice. Proc Natl Acad Sci USA. 95:1998;8806-8811.
65. Bishop-Bailey D., Hla T. Endothelial cell apoptosis induced by the peroxisome proliferator-activated receptor (PPAR) ligand 15-deoxy-Delta12, 14-prostaglandin J2. J Biol Chem. 274:1999;17042-17048.
66. Takahashi N., Okumura T., Motomura W., Fujimoto Y., Kawabata I., Kohgo Y. Activation of PPARgamma inhibits cell growth and induces apoptosis in human gastric cancer cells. FEBS Lett. 455:1999;135-139.
67. Keelan J.A., Sato T.A., Marvin K.W., Lander J., Gilmour R.S., Mitchell M.D. 15-Deoxy-Delta(12,14)-prostaglandin J(2), a ligand for peroxisome proliferator-activated receptor-γ, induces apoptosis in JEG3 choriocarcinoma cells. Biochem Biophys Res Commun. 262:1999;579-585.
68. Xin X., Yang S., Kowalski J., Gerritsen M.E. Peroxisome proliferator-activated receptor gamma ligands are potent inhibitors of angiogenesis in vitro and in vivo. J Biol Chem. 274:1999;9116-9121.
69. Cantello B.C., Cawthorne M.A., Cottam G.P., et al. [[omega-(Heterocyclylamino)alkoxy]benzyl]-2,4-thiazolidinediones as potent antihyperglycemic agents. J Med Chem. 37:1994;3977-3985.
70. Hofmann C.A., Colca J.R. New oral thiazolidinedione antidiabetic agents act as insulin sensitizers. Diabetes Care. 15:1992;1075-1078.
71. Nolan J.J., Ludvik B., Beerdsen P., Joyce M., Olefsky J. Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone. N Engl J Med. 331:1994;1188-1193.
72. Lehmann J.M., Moore L.B., Smith-Oliver T.A., Wilkison W.O., Willson T.M., Kliewer S.A. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma). J Biol Chem. 270:1995;12953-12956.
73. Brown K.K., Henke B.R., Blanchard S.G., et al. A novel N-aryl tyrosine activator of peroxisome proliferator-activated receptor-γ reverses the diabetic phenotype of the Zucker diabetic fatty rat. Diabetes. 48:1999;1415-1424.
74. Berger J., Leibowitz M.D., Doebber T.W., et al. Novel peroxisome proliferator-activated receptor (PPAR) gamma and PPARdelta ligands produce distinct biological effects. J Biol Chem. 274:1999;6718-6725.
75. Hulin B., Newton L.S., Lewis D.M., Genereux P.E., Gibbs E.M., Clark D.A. Hypoglycemic activity of a series of α-alkylthio and α-alkoxy carboxylic acids related to ciglitazone. J Med Chem. 39:1996;3897-3907.
76. Lehmann J.M., Lenhard J.M., Oliver B.B., Ringold G.M., Kliewer S.A. Peroxisome proliferator-activated receptors alpha and gamma are activated by indomethacin and other non-steroidal anti-inflammatory drugs. J Biol Chem. 272:1997;3406-3410.
77. Lefebvre A.M., Chen I., Desreumaux P., et al. Activation of the peroxisome proliferator-activated receptor gamma promotes the development of colon tumors in C57BL/6J-APCMin/+ mice. Nat Med. 4:1998;1053-1057.
78. Saez E., Tontonoz P., Nelson M.C., et al. Activators of the nuclear receptor PPARgamma enhance colon polyp formation. Nat Med. 4:1998;1058-1061.
79. Brockman J.A., Gupta R.A., Dubois R.N. Activation of PPARgamma leads to inhibition of anchorage-independent growth of human colorectal cancer cells [see comments]. Gastroenterology. 115:1998;1049-1055.
80. Sarraf P., Mueller E., Jones D., et al. Differentiation and reversal of malignant changes in colon cancer through PPARgamma [see comments]. Nat Med. 4:1998;1046-1052.
81. Mueller E., Sarraf P., Tontonoz P., et al. Terminal differentiation of human breast cancer through PPAR gamma. Mol Cell. 1:1998;465-470.
82. Tontonoz P., Singer S., Forman B.M., et al. Terminal differentiation of human liposarcoma cells induced by ligands for the peroxisome proliferator-activated receptor γ and the retinoid X receptor. Proc Natl Acad Sci USA. 94:1997;237-241.
83. Demetri G.D., Fletcher C.D., Mueller E., et al. Induction of solid tumor differentiation by the peroxisome proliferator- activated receptor-γ ligand troglitazone in patients with liposarcoma. Proc Natl Acad Sci USA. 96:1999;3951-3956.
84. Lim H., Gupta R.A., Ma W.G., et al. Cyclo-oxygenase-2-derived prostacyclin mediates embryo implantation in the mouse via PPARdelta. Genes Dev. 13:1999;1561-1574.
85. Leibowitz MDF, Hennuyer N, Peinado-Onsurbe J, et al. Activation of PPARδ alters lipid metabolism in db/db mice. 1999, In press.